SION-719 Added to Trikafta for Cystic Fibrosis

SION-719 Added to Trikafta for Cystic Fibrosis
37%21%5%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 32.1%May 28 • YES 10.6%
Sionna Therapeutics Inc. ($SION)
No stock close$44.35$40.56$36.76May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • SION $39.24May 19 • SION $37.68May 20 • SION $39.50May 21 • SION $41.75May 22 • SION $41.13May 26 • SION $42.88May 27 • SION $43.43May 28 • SION $42.80

Will this trial show a positive result on change from baseline in sweat chloride levels?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
7/1/26
Study Completion
7/1/26
Sponsor
Sionna Therapeutics Inc.
Ticker
$SION
Type
Phase 2a
Trial Status
Active, not recruiting
Trial Size
16
NCT
NCT07108153
Trial Description
SION-719 is being tested with Trikafta in adults with cystic fibrosis, mainly tracking side effects through 57 days.